Keytruda and Chemotherapy in Advanced Endometrial Cancer
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
Keytruda and Chemotherapy in Advanced Endometrial Cancer
- August 2, 2023
- Reading time: 1 minute
On June 3, 2023, Dr. Ramez N. Eskander and colleagues from the University of California San Diego published the results of the Phase 3 NRG-GY018 trial in The New England Journal of Medicine. The study evaluated the addition of Keytruda (pembrolizumab) to standard first-line chemotherapy for patients with recurrent or advanced endometrial cancer.
Study Design: The NRG-GY018 trial enrolled 816 patients with Stage III, IVA, IVB, or recurrent endometrial cancer. Participants were randomized 1:1 into two groups:
- Keytruda Group: Keytruda plus chemotherapy (up to 6 cycles every three weeks), followed by Keytruda monotherapy as maintenance (up to 14 cycles every six weeks).
- Placebo Group: Standard chemotherapy plus placebo.
The primary endpoint was progression-free survival (PFS), stratified by mismatch-repair-deficient (dMMR) or mismatch-repair-proficient (pMMR) status.
Clinical Outcomes: The trial results showed significant improvements in PFS for the Keytruda group:
- dMMR Patients: The 12-month PFS rate was 74% in the Keytruda group compared to 38% in the placebo group.
- pMMR Patients: The median PFS was 13.1 months in the Keytruda group versus 8.7 months in the placebo group.
Conclusion: Based on the results of the NRG-GY018 trial, Dr. Ramez N. Eskander and the research team concluded that adding Keytruda to first-line chemotherapy significantly improves progression-free survival in patients with recurrent or advanced endometrial cancer.
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2302312
- Clinical Trial Medications
- Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1